Ivabradina Teva

Ivabradine, the active ingredient in Ivabradina Teva, is an If channel inhibitor presented as a tablet for oral use. It lowers heart rate without affecting contractility and is used to manage chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and transparent pricing.

Ivabradine is an If channel inhibitor used in cardiovascular conditions to control heart rate.

- Chronic stable angina pectoris: reduces frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalizations through heart rate reduction. - Elevated resting heart rate: provides selective heart rate lowering without affecting myocardial contractility.

Ivabradine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes) - Bradycardia - Headache - Dizziness

Serious or Rare Side Effects: - Symptomatic bradycardia - Atrial fibrillation - Severe hypotension - Visual loss

Before prescribing ivabradine, clinicians should consider several safety measures.

- Baseline heart rate assessment: measure resting heart rate before initiating therapy. - Concomitant beta‑blocker use: monitor for excessive bradycardia when combined. - Severe hepatic impairment: avoid or use with caution. - Pregnancy: risk unknown; prescribe only if benefits outweigh risks. - Breastfeeding: not recommended due to insufficient data. - Store at below 25°C: keep in original packaging, protect from moisture.

Ivabradine interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., verapamil, diltiazem): may modestly raise plasma concentrations. - Antidepressants (e.g., fluoxetine, paroxetine): potential increase in exposure. - Diuretics: monitor electrolytes and blood pressure.